sorafenib has been researched along with benzyloxycarbonylleucyl-leucyl-leucine aldehyde in 2 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (benzyloxycarbonylleucyl-leucyl-leucine aldehyde) | Trials (benzyloxycarbonylleucyl-leucyl-leucine aldehyde) | Recent Studies (post-2010) (benzyloxycarbonylleucyl-leucyl-leucine aldehyde) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 2,473 | 3 | 1,057 |
Protein | Taxonomy | sorafenib (IC50) | benzyloxycarbonylleucyl-leucyl-leucine aldehyde (IC50) |
---|---|---|---|
Proteasome subunit beta type-11 | Homo sapiens (human) | 1.9893 | |
Calpain-9 | Homo sapiens (human) | 9.88 | |
Proteasome subunit alpha type-7 | Homo sapiens (human) | 1.9893 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 3.9 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.8999 | |
Aromatase | Homo sapiens (human) | 0.044 | |
Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 0.5 | |
Proteasome subunit beta type-1 | Homo sapiens (human) | 1.0853 | |
Proteasome subunit alpha type-1 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit alpha type-2 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit alpha type-3 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit alpha type-4 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit beta type-8 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit beta type-9 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit alpha type-5 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit beta type-4 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit beta type-6 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit beta type-5 | Homo sapiens (human) | 0.6088 | |
Proteasome subunit beta type-10 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit beta type-3 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit beta type-2 | Homo sapiens (human) | 2.0443 | |
Proteasome subunit alpha type-6 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit alpha-type 8 | Homo sapiens (human) | 1.9893 | |
Proteasome subunit beta type-7 | Homo sapiens (human) | 1.9893 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chao, CC; Kuo, TC; Lu, HP | 1 |
Bertolotto, C; Bourcier, C; Grépin, R; Griseri, P; Mazure, N; Pagès, G | 1 |
2 other study(ies) available for sorafenib and benzyloxycarbonylleucyl-leucyl-leucine aldehyde
Article | Year |
---|---|
The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein.
Topics: Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Eukaryotic Initiation Factor-4E; Humans; Leupeptins; Liver Neoplasms; Neoplasm Proteins; NF-kappa B; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-rel; Pyridines; Sorafenib | 2011 |
Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.
Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Chemokine CXCL5; Dichlororibofuranosylbenzimidazole; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Genes, Reporter; Half-Life; Humans; Immunotherapy, Active; Interleukin-8; Leupeptins; MAP Kinase Kinase Kinases; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyridines; Receptors, Interleukin-8B; RNA Stability; RNA, Messenger; RNA, Small Interfering; Sorafenib; Transfection; Tristetraprolin; Tumor Cells, Cultured; Vaccination | 2011 |